evidence varies by claim

Cagrilintide

Metabolic & Endocrine

Cagrilintide is indexed as peptide in the PeptideBase article library. It is referenced in “CagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy” and 1 other PeptideBase article. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.

Research status: evidence varies by claim

Deep Dives on Cagrilintide

Start here for the plain-English articles connected to this peptide.

metabolic9 min read

GIP Agonism vs Antagonism: Why Opposite Strategies Can Both Reduce Food Intake in Mice

A 2026 mouse study suggests GIPR agonism and antagonism can affect food intake and body weight through distinct brain regions—not interchangeable mechanisms.

Read article

metabolic8 min read

CagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy

A cautious, evidence-aware explainer on CagriSema, the investigational semaglutide plus cagrilintide combination, and why the amylin + GLP-1 strategy is not just stronger semaglutide.

Read article

Quick Facts

Origin: Named peptide referenced in PeptideBase coverage
Category: Metabolic & Endocrine

Research Areas